Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Premedication for IANB Success in Symptomatic Irreversible Pulpitis
NCT05097768Completed
- Sponsor
- Al-Farabi Private Colleges
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexamethasone, ketorolac, meloxicam and ibuprofen in irreversible pulpitis, sponsored by Al-Farabi Private Colleges. Started Aug 2021; status: completed.
02
Drugs
dexamethasoneketorolacmeloxicamibuprofen
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT05097768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097768.